

6 June 2023

Diaceutics PLC
("Diaceutics" or "the Company")

Purchase and Sale of Shares and PDMR Shareholdings

[Diaceutics PLC](#), (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry announces the following Director and PDMR share dealing.

On 5 June 2023, Nick Roberts, CFO of Diaceutics, purchased 21,742 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 91.75 pence per Ordinary Share. As a result of the purchase, Nick's shareholding is 62,576 Ordinary Shares, representing approximately 0.07% of the Company's issued share capital.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison
Nick Harland
Nick Adams
Kate Hanshaw

Tel: +44 (0)20 7710 7600

Alma PR

Caroline Forde
Kieran Breheny
Matthew Young
Kinvara Verdon

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Nick Roberts
2 Reason for notification		
a.	Position/Status	CFO
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Purchase				
c.	Price(s) and volume(s)	Share purchase: <table border="1" data-bbox="600 427 1059 566"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>91.75p</td> <td>21,742</td> </tr> </tbody> </table>	Price(s)	Volume(s)	91.75p	21,742
Price(s)	Volume(s)					
91.75p	21,742					
d.	Date of the transaction	5 June 2023				
e.	Place of the transaction	AIM Market of the London Stock Exchange				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFFFLLIRRIEIV